Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sulzer's Inter-Op

This article was originally published in The Gray Sheet

Executive Summary

Recalled hip implant recipient Rhonda Silva files product liability lawsuit Jan. 19 through Lieff, Cabraser, Heimann & Bernstein against Sulzer Orthopedics parent Sulzer Medica in California Superior Court in Alameda County. Although Sulzer issued a Dec. 8 press release announcing the recall, the plaintiff alleges that the Swiss company failed to issue warnings of the defect to physicians and the general public following reports of the defective acetabular shells as early as October 1999 (1"The Gray Sheet" Jan. 22, 2001, p. 14)

You may also be interested in...



Sulzer Inter-Op Hip Shell Loosening Detected In 129 Patients Following Recall

The financial impact of Sulzer Orthopedics' Inter-Op acetabular shell hip implant recall Dec. 5 "will be more than offset" by a $32 mil. one-time payment from a separate litigation settlement to its Sulzer Spine-Tech subsidiary, the firm predicts.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel